BritePear› 🍐 Peptide You› CJC-1295 + Ipamorelin
Peptide You · Body Composition
Phase I/II Clinical Data · Investigational

CJC-1295 + Ipamorelin: The Growth Hormone Stack

Why these two peptides are almost always discussed together, and what it means for body composition, sleep, and recovery.

🍐 Pear It Down ,

CJC-1295 and Ipamorelin are two peptides often used together to stimulate the body's own growth hormone release in a natural, pulsatile pattern. CJC-1295 is a GHRH analog. Ipamorelin is a selective GH secretagogue with a clean side effect profile. Together they work synergistically. Both are investigational and not FDA-approved for general use.

Not medical advice. Educational information reflecting personal research and transparency. Always work with a qualified healthcare provider before starting any peptide protocol. Verify current compounding regulations in your state.

This is one of the most discussed stacks in the peptide world, and once you understand the mechanism it makes complete sense why. These two compounds work on the same system, your growth hormone axis, but from different angles, creating an effect that's greater than either alone.

The System

Your Growth Hormone Axis, Briefly

Your pituitary gland releases growth hormone in pulses throughout the day, with the largest pulse typically occurring during deep sleep. GH drives fat metabolism, muscle protein synthesis, tissue repair, and cellular regeneration. As we age, these GH pulses become less frequent and less robust, starting as early as the mid-twenties.[1]

Two signals regulate this release from the hypothalamus: Growth Hormone-Releasing Hormone (GHRH), which triggers release, and somatostatin, which suppresses it. The balance between these determines how much GH you produce.

CJC-1295

The GHRH Analog

CJC-1295 is a synthetic peptide that mimics GHRH, it binds to GHRH receptors in the pituitary and stimulates GH release. The modified version (with DAC, Drug Affinity Complex) has a much longer half-life than natural GHRH, meaning fewer injections are needed to sustain the signal.[2]

Clinical studies in healthy adults demonstrated that CJC-1295 produced dose-dependent increases in GH and IGF-1 with a favorable safety profile.[3]

Ipamorelin

The Clean GH Secretagogue

Ipamorelin works differently, it's a selective GH secretagogue that mimics the hormone ghrelin, binding to ghrelin receptors in the pituitary to stimulate GH release. What makes it well-regarded is selectivity: unlike older GH secretagogues, it does not significantly raise cortisol, prolactin, or ACTH, hormones you generally don't want chronically elevated.[4]

"The appeal of this stack is that it works with your body's existing feedback system rather than bypassing it. You're stimulating your pituitary to release your own GH in natural pulses, not injecting synthetic HGH directly."

Why Together

The Muscle Preservation Angle

One of the most significant concerns on any aggressive weight loss protocol, GLP-1 or otherwise, is losing lean muscle alongside fat. GH plays a key role in protein synthesis and muscle preservation. This is part of why the CJC-1295/Ipamorelin conversation has grown among people on GLP-1 medications looking to protect body composition.[8]

⚠ FDA / Regulatory StatusCJC-1295 and Ipamorelin are not FDA-approved for general use. Both are considered investigational compounds. The FDA has restricted their use in compounding in some contexts. Always work with a licensed physician for any GH peptide protocol and verify current compounding regulations in your state.

Sources & Citations

  1. Giustina A & Veldhuis JD (1998). Pathophysiology of the neuroregulation of growth hormone secretion. Endocrine Reviews, 19(6), 717–797.
  2. Jetté L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295. Journal of Medicinal Chemistry, 48(1), 279–285.
  3. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
  4. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
  5. Johansen PB, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide. Growth Hormone & IGF Research, 9(2), 106–113.
  6. Bowers CY (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329.
  7. Rudman D, et al. (1990). Effects of human growth hormone in men over 60 years old. New England Journal of Medicine, 323(1), 1–6.
  8. Treuth MS, et al. (1994). Effects of GH on body composition in older men. Journal of Applied Physiology, 77(6), 2663–2671.